Artwork

Content provided by Scott Nelson. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Scott Nelson or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Shaping the Future of Alzheimer’s Care: Interview with Sinaptica CEO Ken Mariash

25:20
 
Share
 

Manage episode 393333361 series 2926001
Content provided by Scott Nelson. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Scott Nelson or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

In this episode of Medsider Radio, we had an enlightening conversation with Ken Mariash, a leading figure in the neuromodulation space and the CEO of Sinaptica Therapeutics, where his team is developing groundbreaking treatments for Alzheimer's disease. Their device delivers non-invasive neuromodulation therapy to key networks of the brain and has shown unprecedented improvement in treating this debilitating disease.

Ken's two decades of experience leading sophisticated organizations has taken him from management consulting at Charles River Associates to significant roles at CSL, Baxter, and Boston Scientific. During his time at Boston, Ken was instrumental in commercialization and strategy development in the company’s $1B neuromodulation division.

In this interview, Ken shares his time-tested wisdom, covering a range of topics from kick-starting a venture and how to approach M&A transactions, to mastering commercialization and best practices for engaging with investors.

Before we dive into the discussion, I wanted to mention a few things:

First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.

Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!

We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and a curated investor database to help you discover your next medical device or health technology investor!

In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, if you'd rather read than listen, here's a link to the full interview with Ken Mariash.

  continue reading

173 episodes

Artwork
iconShare
 
Manage episode 393333361 series 2926001
Content provided by Scott Nelson. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Scott Nelson or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

In this episode of Medsider Radio, we had an enlightening conversation with Ken Mariash, a leading figure in the neuromodulation space and the CEO of Sinaptica Therapeutics, where his team is developing groundbreaking treatments for Alzheimer's disease. Their device delivers non-invasive neuromodulation therapy to key networks of the brain and has shown unprecedented improvement in treating this debilitating disease.

Ken's two decades of experience leading sophisticated organizations has taken him from management consulting at Charles River Associates to significant roles at CSL, Baxter, and Boston Scientific. During his time at Boston, Ken was instrumental in commercialization and strategy development in the company’s $1B neuromodulation division.

In this interview, Ken shares his time-tested wisdom, covering a range of topics from kick-starting a venture and how to approach M&A transactions, to mastering commercialization and best practices for engaging with investors.

Before we dive into the discussion, I wanted to mention a few things:

First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.

Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!

We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and a curated investor database to help you discover your next medical device or health technology investor!

In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, if you'd rather read than listen, here's a link to the full interview with Ken Mariash.

  continue reading

173 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide